Novo Nordisk is the Danish drugmaker behind Ozempic and Wegovy, the famous weight-loss and diabetes injections.
Novo Nordisk A/S (NVO) is expected to report earnings on Wednesday, November 4, 2026, after the close. Consensus EPS estimate is $0.74.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $0.77 | $0.96 | — | $12.13B |
| 2026-05-06 | Mar 2026 qtr | $0.87 | $1.04 | — | $11.02B |
| 2026-02-03 | Dec 2025 qtr | $0.90 | $1.00 | +11.1% | — |
| 2025-11-05 | Sep 2025 qtr | $0.77 | $1.02 | — | — |
| 2025-08-06 | Jun 2025 qtr | $0.93 | $0.97 | +4.3% | — |
| 2024-09-30 | Sep 2024 qtr | $0.87 | $0.88 | — | $10.68B |
| 2024-06-30 | Jun 2024 qtr | $0.70 | $0.66 | -5.9% | $9.80B |
| 2024-03-31 | Mar 2024 qtr | $0.74 | $0.82 | +10.5% | $9.38B |
NVO has beaten consensus EPS in 3 of its last 4 scored quarters.
NVO pays a semi-annual dividend, currently yielding 4.00%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-08-17 | $0.5792 | 2026-08-25 |
| 2026-03-30 | $1.2174 | 2026-04-08 |
| 2025-08-18 | $0.5843 | 2025-08-26 |
| 2025-03-31 | $1.1426 | 2025-04-08 |
| 2024-08-16 | $0.5169 | 2024-08-26 |
| 2024-03-22 | $0.9293 | 2024-04-02 |